On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser. In March, the FDA cleared Dexcom’s Stelo, making it the first glucose ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ ... Though the policy uncertainty will take time to recede, there are expectations that antitrust regulation will be ...

They've all been run with DexCom, at least with our pump partners, and that's the data they publish for their time in range. Look, we serve, several hundred thousand AID system users right now and ...

Amid the launch of its first over-the-counter wearable glucose tracker, Dexcom reported that its overall revenues in the U.S. declined year over year despite overall sales coming in slightly ...

DexCom Inc. (DXCM) on Thursday reported third-quarter earnings of $134.6 million. The San Diego-based company said it had net income of 34 cents per share. Earnings, adjusted for one-time gains ...

Dexcom (DXCM – Research Report), the Healthcare ... platform and the FDA submission for the G7 device with extended wear time are positive indicators for the company’s growth and ...

DXCM Price Action: According to Benzinga Pro, DexCom shares are down 7.94% after-hours at $68.91 at the time of publication Thursday.

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago.

DexCom (NASDAQ:DXCM) reported third-quarter earnings that surpassed analyst expectations, but the company's stock plummeted 16% as revenue growth slowed significantly. The continuous glucose ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat ... fourth-quarter and "get more and more effective over time". Shares recouped some lost ground and were last down ...

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at $75.00. Patrick Wood has given his Hold rating due to a ...